Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avatrombopag versus placebo in pediatric immune thrombocytopenia
2020-003232-24Phase 3Completed
- Sponsor
- Dova Pharmaceuticals, Inc.
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of avatrombopag in immune thrombocytopenia (ITP) (3 arms), sponsored by Dova Pharmaceuticals, Inc. Primary endpoint: Primary efficacy endpoint. Started Oct 2020; status: completed.
02
Drugs
avatrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2020-003232-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003232-24.